Benzinga | May 3, 2021 08:31AM EDT

Galmed Announces Approval Of IND Application In China For Aramchol For Treatment Of NASH & Fibrosis In Global Phase 3 ARMOR Registrational Study

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the National Medical Products Administration (NMPA) has granted approval for the Investigational New Drug (IND) application for Galmed's Phase 3 ARMOR registrational study of Aramchol for the treatment of NASH & Fibrosis.